WAKIX funds the next act
- Harmony’s business still depends on WAKIX, its narcolepsy drug and current sole revenue source.
- Q2 2026 WAKIX net revenue reached $261.3 million, up 30% year over year.
- Management kept 2026 net revenue guidance at $1.0 billion to $1.04 billion.
- The FDA accepted the Pitolisant GR application, setting a target decision date of April 1, 2027.
- The main risk is that generic lawsuits or new sleep drugs hit WAKIX before the pipeline is ready.
One strong drug, many clocks
Harmony is a rare brain disease drug company, but the stock is still mostly a WAKIX story. WAKIX treats narcolepsy, a sleep disorder that can cause extreme daytime sleepiness and sudden muscle weakness. In Q2 2026, WAKIX net revenue hit a record $261.3 million, and management kept full-year 2026 guidance at $1.0 billion to $1.04 billion.
The bull case relies on WAKIX generating cash to fund new versions of pitolisant and rare epilepsy drugs. BP-205, a new orexin-2 agonist, recently showed promising early safety and dosing data that supports a once-daily pill. Harmony also holds significant cash to buy or license assets that could bring revenue in the 2028 to 2032 period.
The bear case centers on timing. WAKIX is doing all the heavy lifting while pipeline assets wait on data or FDA review. The TEMPO study for Prader-Willi syndrome was pushed to mid-2027 due to enrollment constraints. Also, the bench trial for the AET patent litigation wrapped up, with closing arguments set for October 2026. A bad ruling could change the generic entry timeline.
Finn’s overall view is balanced. Growth and financial health look solid, but sentiment is weaker because investors still need proof that Harmony can become more than one big product.
WAKIX pays the bills
Harmony makes money by selling prescription medicine in the United States. Today, that means WAKIX. The company reports one business segment, and all current revenue comes from net product sales of WAKIX.
WAKIX is non-scheduled, meaning it is not treated as a controlled substance under federal drug scheduling. That helps set it apart in narcolepsy, where some treatments have stricter handling rules. Harmony’s commercial job is to add patients, keep doctors using WAKIX, and defend pricing and coverage.
The strategy is to stretch the pitolisant franchise through new formulations such as Pitolisant GR and Pitolisant HD. At the same time, Harmony is trying to add new engines in rare epilepsy and other CNS diseases. CNS means central nervous system, which includes the brain and spinal cord.
Where it breaks is concentration. If WAKIX slows, loses patent protection earlier than expected, or faces a better new class of drugs, the company has fewer backup revenue streams today.
What Harmony owns
WAKIX
WAKIX is pitolisant for narcolepsy in adult and pediatric patients age 6 and older. It is Harmony’s only commercial product and its sole revenue source.
Pitolisant GR
Pitolisant GR is a gastro-resistant version of pitolisant. The FDA accepted the application for full review with a target decision date of April 1, 2027.
Pitolisant HD
Pitolisant HD is a higher-dose formulation being tested in Phase 3 trials for narcolepsy and idiopathic hypersomnia. Topline data are expected in 2027, with a target FDA decision in 2028.
New pitolisant formulation
Harmony is developing a new pitolisant formulation for broader CNS uses outside sleep and wake disorders. Q1 2026 license deals with Novitium and MSN added intellectual property to support this plan.
BP-205
BP-205 is an orexin-2 receptor agonist. Phase 1 single-ascending-dose data showed a 25-hour half-life supporting once-daily dosing, with multiple-ascending-dose data expected in Q4 2026.
EPX-100
EPX-100 is in Phase 3 trials for Dravet syndrome and Lennox-Gastaut syndrome, two rare epilepsy disorders. Topline Dravet data are expected in mid-2027.
ZYN-002
ZYN-002, also called Zygel, failed its Phase 3 RECONNECT trial in Fragile X syndrome. The program is paused while Harmony reviews the data.
Reported as one business
Harmony reports one integrated pharmaceutical segment. For Q2 2026, all current revenue came from WAKIX net product sales in the United States, while the pipeline produced no product revenue.
What could break the story
Patent cliff moves closer
High impact · Medium oddsThe bench trial against AET defending WAKIX patents has concluded, with closing arguments scheduled for October 22, 2026. A bad ruling could pull forward generic WAKIX risk before new products are ready.
WAKIX growth slows
High impact · Medium oddsThe 2026 plan depends on WAKIX reaching $1.0 billion to $1.04 billion in net revenue. If patient adds slow, payer access worsens, or prescriptions flatten, Harmony’s cash engine weakens. That would make pipeline funding and dealmaking harder.
Orexin competition changes sleep medicine
Medium impact · Medium oddsNew orexin agonists could become important competitors. Harmony has its own orexin-2 agonist, BP-205, but it still needs more human data. If rival drugs show better results first, WAKIX could face a tougher market.
Trial timelines slip
Medium impact · Medium oddsHarmony is running several studies in rare CNS conditions. Rare disease trials can be hard to enroll. The Phase 3 TEMPO study in Prader-Willi syndrome was pushed to mid-2027 due to enrollment constraints, leaving the company tied to WAKIX for longer.
Deals do not fill the gap
Medium impact · Medium oddsManagement wants business development assets that could generate revenue in the 2028 to 2032 window. Harmony has cash, but good near-commercial rare disease assets can be expensive. Paying too much or buying weak data would hurt returns.
In one breath
What does Harmony Biosciences sell?
Harmony sells WAKIX, a narcolepsy drug. It is approved for excessive daytime sleepiness and cataplexy in adult and pediatric patients age 6 and older.
Why is WAKIX so important to HRMY stock?
WAKIX is Harmony’s only commercial product and sole revenue source. Its cash flow funds new pitolisant versions, rare epilepsy trials, and possible acquisitions.
What are Harmony’s biggest upcoming catalysts?
Key events include the October 2026 AET patent litigation closing arguments, BP-205 data in late 2026, the Pitolisant GR FDA decision in April 2027, and EPX-100 data in mid-2027.
What is the biggest risk for Harmony Biosciences?
The biggest risk is that WAKIX loses momentum or faces generic competition earlier than expected. That would matter most if pipeline products are not ready to replace the revenue.
